In This Section

Can Metabolic Vulnerabilities in Tumors be Therapeutically Exploited?

Tuesday April 24, 2018

9:30 am - 12:00 pm Eastern Time (ET)

Room 15A


Chair :

Susan Cole
Queen's University at Kingston

Koen van de Wetering
Thomas Jefferson University

Many metabolic pathways are altered in cancer cells, which sometimes rely heavily on specific nutrients. Significant progress has been made in recent years in our understanding of how these metabolic changes may lead to vulnerabilities in different tumor types that may be harnessed for therapeutic benefit. This symposium will provide insights into the strategies used to identify these vulnerabilities and how they may be exploited in anticancer therapy.


Gary Siuzdak - The Scripps Research Institute

Modulating the Oncogenic Phenotype with Metabolites

Heather Christofk - University of California, Los Angeles

Metabolic Transitions in Cancer: Lessons from Viral Infection

Boyi Gan - The University of Texas MD Anderson Cancer Center

The Glutamate/Cystine Antiporter SLC7A11/xCT Regulates Glucose Dependency in Cancer Cells: Mechanism and Therapeutic Implications

Koen van de Wetering - Thomas Jefferson University

ABBC5: A Multidrug Efflux Transporter with an Unusual Substrate Spectrum

Heather True - School of Pharmacy, Pacific University Oregon

Raloxifene Compromises Mitochondria, Induces ROS Stress and the Unfolded Protein Response, and Synergizes Gemcitabine's Cytotoxicity in Pancreatic Cancer Cells

Bettine Gibbs - Butler University

Molecular Targeting and Inactivation of Glutaminase and CDK4/6 in Mantle Cell Lymphoma